Tempus and Stemline Therapeutics Announce Collaboration to Implement Tempus Next to Support Patients with Metastatic Breast Cancer

“We are thrilled to enter this collaboration with Tempus, a leader in leveraging AI to advance precision medicine and patient care. ESR1 mutations can stop tumors from responding to standard endocrine therapy, in turn causing the cancer to progress. With an approved treatment that targets these mutations, the identification of ESR1 is a critical step in customizing care for patients with ER+, HER2- metastatic breast cancer,” said Yasir Nagarwala, Senior Vice President, Medical Affairs, Stemline Therapeutics, Inc. “At Menarini Stemline, we are focused on bringing transformational therapies to patients living with cancer, and by partnering with companies like Tempus, we are able to help physicians understand when testing for an ESR1 mutation may be appropriate.”
Share:
More News
PharmaMar has submitted a Marketing Authorization Application to the European Medicines Agency for Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer, whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide. The MAA submission
“At SR One, our mission is to invest in companies that we believe have the ability to innovate and advance transformational new therapies in areas of high unmet medical need,” said Simeon George, M.D., Chief Executive Officer and Managing Partner at SR One. “Fore Bio is focused on resetting the
The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of TACE-progression-free survival (TACE PFS*), and the other primary endpoint of overall survival (OS) is immature at the prespecified first interim analysis. Meanwhile, a clinically meaningful PFS by RECIST v1.1** was also observed. Detailed findings from
“The positive CHMP recommendation for the Itovebi-based regimen represents a significant step towards providing people in the EU with PIK3CA-mutated, ER-positive advanced breast cancer with a targeted therapy in the first-line setting,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This recommendation is